Prostate cancer is the most common male malignancy in most
European countries with over 200 000 new cases diagnosed each year in
Europe. The widespread use of prostate specific antigen (PSA) tests on
asymptomatic men and an aging population leads to a high rate of
over-detection and subsequent over-treatment of the disease as there are
currently no tools to reliably identify patients who need aggressive
The lack of knowledge of the molecular mechanisms of the development and progression of prostate cancer has hampered the development of better prevention, diagnostics, prognostics, and therapeutic tools. In addition to the androgen signalling pathway, no major mechanisms of prostate cancer growth have been identified. The recent breakthrough discovery of the importance of non-coding RNAs (ncRNAs) in the development of malignancies has revealed that ncRNAs may play a key role in the development and progression of prostate cancer.
The general aim of this multidisciplinary project is to elucidate the role of ncRNAs in the development of prostate cancer and evaluate the utility of ncRNAs as diagnostic and prognostic tools and as therapy targets in clinical practice.
ProspeR is a collaborative, small or medium-scale focused research project subsidised by the European Commission through the 7th Framework Program.